Skip to main content

Table 4 Demographic characteristic of HCC patients with BCLC 0 and A stage

From: Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma

Variables

Hepatectomy (n = 126)

LT (n = 53)

P-value

Age (years)

49.9 ± 11.1

49.9 ± 11.2

0.892

Gender, M/F

121 (96.0%)/5 (4.0%)

50 (98.4%)/3 (1.6%)

0.671

AFP (ng/ml), ≤ 400/ > 400

82 (65.1%)/34 (34.9%)

42 (79.2%)/11 (20.8%)

0.243

HBV-DNA, ± 

88 (69.8%)/38 (30.1%)

26 (49.1%)/27 (50.9%)

0.008

Prothrombin time (s)

13.6 ± 1.2

14.6 ± 3.2

0.001

FIB-4

2.5 ± 1.9

2.7 ± 1.5

0.464

Tumor size (cm), < 5/ ≥ 5

76 (60.3%)/50 (49.7%)

28 (52.8%)/25 (47.2%)

0.354

Tumor nodule number, Single / Multiple (≥ 2)

122 (96.8%)/4 (3.2%)

50 (94.4%)/3 (5.6%)

0.433

MVI, ± 

14 (11.1%)/112 (88.9%)

16 (30.2%)/37 (69.8%)

0.002

Differentiation gradea, I–II/III–IV

118 (93.7%)/8 (6.3%)

47 (88.7%)/6 (11.3%)

0.258

BCLC stage, 0/A

20 (15.9%)/106 (84.1%)

12 (22.6%)/41 (77.4%)

0.281

  1. HCC hepatocellular carcinoma, BCLC Barcelona Clinic Liver Cancer, LT liver transplantation, AFP alpha-fetoprotein, MVI microvascular invasion, HCC hepatocellular carcinoma
  2. aEdmondson-Steiner grade